{
    "name": "halobetasol topical",
    "comment": "Rx",
    "other_names": [
        "Ultravate",
        "Bryhali",
        "Lexette"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/ultravate-bryhali-halobetasol-topical-343653",
    "pregnancy": {
        "common": [
            "Data are unavailable for use in pregnant women to inform any drug associated risks for birth defects or miscarriage; published data report an increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Systemic administration during organogenesis to pregnant rats at 13-33 times the human topical dose and to pregnant rabbits at 3 times the human topical dose resulted in teratogenic and embryotoxic effects"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects in infant",
            "Unknown whether topical corticosteroids result in sufficient systemic absorption to produce detectable quantities in human milk",
            "Advise breastfeeding women not to apply halobetasol directly to the nipple and areola to avoid direct infant exposure"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic topical corticosteroid therapy may interfere with growth and development in children",
                "Use medium to very high potency topical corticosteroids for <2 wk to reduce local and systemic side effects",
                "Use low-potency topical corticosteroids for chronic therapy",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Kaposi sarcoma reported with prolonged corticosteroid therapy",
                "Local effects may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria; these effects more likely with prolonged use, occlusive dressings, or higher potency corticosteroids (eg, halobetasol); some local adverse reactions may be irreversible",
                "May increase risk of posterior subcapsular cataracts and glaucoma (reported in postmarketing experience with topical corticosteroids); advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation",
                "Use an appropriate antimicrobial agent if a skin infection is present or develops; if a favorable response does not occur promptly, discontinue use until infection has been adequately treated; if infection continues, discontinue halobetasol",
                "Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation; consider confirming allergic contact dermatitis with patch test; discontinue therapy if allergic contact dermatitis is established"
            ],
            "specific": [
                {
                    "type": "Effects on endocrine system",
                    "description": [
                        "Therapy has been shown to suppress hypothalamic-pituitary-adrenal (HPA) axis; systemic effects of topical corticosteroids may include reversible HPA axis suppression, with potential for glucocorticosteroid insufficiency; this may occur during treatment or upon withdrawal of treatment of the topical corticosteroid",
                        "Systemic effects of topical corticosteroids may also include Cushingâ€™s syndrome, hyperglycemia, and glucosuria; use of more than one corticosteroid-containing product at the same time may increase total systemic exposure to topical corticosteroids",
                        "Pediatric patients may be more susceptible than adults to systemic toxicity from use of topical corticosteroids due to their larger surface-to-body mass ratios",
                        "Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of more potent corticosteroids, use over large surface areas, prolonged use, occlusive use, use on an altered skin barrier, concomitant use of multiple corticosteroid-containing products, liver failure, and young age; an ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression",
                        "If HPA axis suppression is documented, attempt to gradually withdraw drug, reduce frequency of application, or substitute a less potent steroid; manifestations of adrenal insufficiency may require supplemental systemic corticosteroids; recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Telangiectasia",
            "percent": "1"
        },
        {
            "name": "Application site atrophy",
            "percent": "1"
        },
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Skin atrophy",
            "percent": "2"
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Acneform lesions",
            "percent": null
        },
        {
            "name": "Intracranial hypertension",
            "percent": null
        },
        {
            "name": "Allergic contact dermatitis",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Pustulation",
            "percent": null
        },
        {
            "name": "Perioral dermatitis",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Hypertrichosis",
            "percent": null
        },
        {
            "name": "Leukoderma",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "acneiform eruptions",
            "percent": null
        },
        {
            "name": "hypopigmentation",
            "percent": null
        },
        {
            "name": "perioral dermatitis",
            "percent": null
        },
        {
            "name": "allergic contact dermatitis",
            "percent": null
        },
        {
            "name": "secondary infection",
            "percent": null
        },
        {
            "name": "irritation",
            "percent": null
        },
        {
            "name": "striae",
            "percent": null
        },
        {
            "name": "and miliaria",
            "percent": null
        }
    ]
}